

07 September 2021

## India Pharma

Sensex: 58279

*Recovery in volumes, non-Covid drugs pushed up IPM growth to 18%*

Nifty: 17362

Driven by a volume bounce-back and recovery in sales of non-Covid'19 sales, the India Pharma Market grew 17.7% in Aug. The non-Covid-19 drug range, which makes up 63% of the market, is now growing in mid-teens, while the Covid-19 portfolio still continues to grow faster. In Aug, volumes aided 9% growth while price growth was 5.9%, and 2.9% from launches. Acute therapy sales grew at a strong 24.5%, while chronic and sub-chronic therapies grew 10.1% and 14.7% respectively. Ipcा, Ajanta, Indoco and FDC were front-runners of growth in Aug.

**Ipcा grew fastest in Aug:** Growth in select chronic drug companies was much better with Sun registering 20.9% growth, Torrent 22.5%, Ipcा 38.5% and Ajanta 31.7%. Acute-therapy companies also did well in Aug, Alkem (sales growth: 21.2%), Dr Reddy's (26.4%), Indoco (33%), FDC (33.6%), grew faster. Glenmark (down 17%) and Natco (30.8%), though, reported a decline in sales in Aug'21.

**Strong recovery unfolding in acute therapies:** Sales of acute-therapy products had borne the maximum brunt of the Covid-19 pandemic. While growth in the initial months of FY22 was driven by Covid-19 drugs, non-Covid'19 drugs too have now started growing faster. Anti-infective therapies grew 29.2%, respiratory 38.2%, gastrointestinal 21.9%. Pain management is the only acute therapy which had not seen any major benefit of Covid-19 but has still grown 32.4%.

**Gathering pace in chronic therapies:** Volumes in chronic therapies continue to be lower due to the change in prescription patterns last year. Sales of cardiac products grew 6.3%, anti-diabetes 8.6%. Vitamins, which had benefited from the Covid-19 outbreak, is now however seeing moderation in growth, and was up 10.6% in August.

**Better MNC performance:** Performance of MNCs improved from Jul'21. Glaxo (18.6%) and the Abbott group (14.6%) grew in double digits, while growth for Sanofi (9.2%) and Pfizer (8.2%) is catching up.

**Our view.** The IPM is expected to grow in mid-teens ahead, in line with its past average. In the near term, recovery in volumes and higher acute-therapy sales would boost market growth. In the long run, though, factors such as greater availability of medicines and healthcare facilities would be crucial. Chronic therapies would outstrip acute therapies in the long run as emerging lifestyle diseases boost demand for chronic drugs. The sector continues to hike prices 5-6% while launches will contribute markedly to growth.

We continue to prefer companies with strong chronic-therapy ranges, and maintain our positive view on Abbott India, Pfizer India, Torrent and Ajanta.

AbdulkaderPuranwala  
Research Analyst

## Sector Overview

Fig 1 – Monthly growth trend of the IPM

*Strong growth rebound on a lower base*




Fig 2 – Performances of listed companies

*Ipca, FDC, Indoco, Ajanta and Dr Reddy's were the front-runners of growth in Aug*




Fig 3 – Performances of key therapies

*Acute therapies leading the growth momentum*





Fig 4 – Past growth break-up, IPM


A ~6% blended price hike for the sector; ~3% growth from launches



Source: AIOCD

Fig 5 – Q1 and Q4 have in the past been weak quarters for the IPM


Q1 FY21 had been the weakest; hence, growth in Q1 FY22 appeared higher



Source: AIOCD


Fig 6 – Performances of key favipiravir brands

Glenmark's Fabiflu sales have come down from Rs2.1bn in May to Rs162m in Aug



Source: AIOCD

Fig 7 – Performances of key remdesivir brands



Source: AIOCD


## Abbott

Fig 8–Performances of its top-10 brands


Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Mixtard	Human Premix Insulin	Anti Diabetic	Chronic	5,836	5.5	493	19.5
Thyronorm	Levo-Thyroxine	Hormones	Chronic	3,972	14.1	349	28.0
Udiliv	Ursodeoxycholic Acid	Gastro Intestinal	Acute	3,746	31.7	385	54.7
Novomix	Biphasic Aspart	Anti Diabetic	Chronic	3,241	4.5	250	-4.1
Duphaston	Dydrogesterone	Gynaecological	Sub Chronic	2,958	-8.5	232	10.9
Vertin	Betahistine	Neuro / Cns	Sub Chronic	2,269	23.5	205	25.7
Duphalac	Lactulose	Gastro Intestinal	Acute	2,202	26.7	228	47.2
Phensedyl Cough Linctus	Chlorpheniramine + Codeine	Respiratory	Acute	2,001	-25.3	9	-95.6
Limcee	Plain Vitamin C	Vitamins / Minerals / Nutrients	Sub Chronic	1,938	169.4	94	-15.9
Actrapid	Regular Human Insulin	Anti Diabetic	Chronic	1,906	34.3	151	10.2
			Overall	102,453	14.5	8,746	14.6

Source: AIOCD

Fig 9 – Performances of its topbrands





Source: AIOCD




Source: AIOCD

Fig 10 – Growth across key therapies



Source: AIOCD

Fig 11 – Growth break-up for company and its top 5 brands (%)



Source: AIOCD


## Ajanta Pharma

Fig 12– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Met XI	Metoprolol	Cardiac	Chronic	1,358	16.5	118	12.4
AtorfitCv	Atorvastatin + Clopidogrel	Cardiac	Chronic	571	9.2	57	31.7
Melacare	Hydroquinone + Mometasone + Tretinoin	Derma	Chronic	510	-0.9	36	-27.1
Rosutor Gold	Aspirin + Rosuvastatin + Clopidogrel	Cardiac	Chronic	484	59.4	47	44.1
Feburic	Febuxostat	Pain / Analgesics	Acute	462	23.8	46	23.5
Cinod	Cilnidipine	Cardiac	Chronic	347	18.4	35	14.2
Met XI Am	Metoprolol + Amlodipine	Cardiac	Chronic	327	12.9	28	2.6
RosufitCv	Rosuvastatin + Clopidogrel	Cardiac	Chronic	274	19.2	24	10.9
Vertizac	Cinnarizine + Dimenhydrinate	Neuro / Cns	Sub Chronic	186	41.2	15	21.3
Soft Drops	Carboxy Methyl Cellulose	Ophthal / Otologicals	Acute	182	20.7	16	26.9
		Overall		10,704	21.7	1,014	31.7


Source: AIOCD

Fig 13 – Performances of its topbrands




Source: AIOCD

Fig 14 – Growth across key therapies



Source: AIOCD

Fig 15 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Alembic Pharma

Fig 16– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Azithral	Azithromycin	Anti-Infectives	Acute	2,741	50	230	21
Althrocin	Erythromycin	Anti-Infectives	Acute	872	-2	82	-7
Wikoryl	Paracetamol + Phenylephrine + Chlorpheniramine	Respiratory	Acute	631	-5	73	86
Gestofit	Natural Micronised Progesterone	Gynaecological	Sub Chronic	467	16	39	12
Ulgel	Magaldrate + Simethicone	Gastro Intestinal	Acute	443	9	34	-17
Roxid	Roxithromycin	Anti-Infectives	Acute	440	-17	43	5
Crina N	Norethisterone	Gynaecological	Sub Chronic	321	20	29	16
Rekool D	Domperidone + Rabeprazole	Gastro Intestinal	Acute	305	18	30	23
Richar	Iron + Folic Acid	Gynaecological	Sub Chronic	290	18	29	34
Cetanil-T	Cilnidipine + Telmisartan	Cardiac	Chronic	277	22	24	13
Overall				18,394	9.8	1,671	16.7


Source: AIOCD

Fig 17 – Performances of its top brands




Source: AIOCD

Fig 18 – Growth across key therapies



Source: AIOCD

Fig 19 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD

## Alkem Laboratories

Fig 20– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Clavam	Amoxicillin + Clavulanic Acid	Anti-Infectives	Acute	3,754	4	344	19
Pan	Pantoprazole	Gastro Intestinal	Sub Chronic	3,563	12	321	6
Pan D	Domperidone + Pantoprazole	Gastro Intestinal	Acute	3,081	16	258	-1
A To Z Ns	Multivitamins + Minerals	Vitamins / Minerals / Nutrients	Sub Chronic	2,597	38	220	2
Taxim O	Cefixime	Anti-Infectives	Acute	2,144	-3	228	35
Xone	Ceftriaxone	Anti-Infectives	Acute	1,952	27	190	24
Gemcal	Calcium Carbonate + Calcitriol + Zinc	Vitamins / Minerals / Nutrients	Sub Chronic	1,437	5	126	4
Pipzo	Piperacillin + Tazobactam	Anti-Infectives	Acute	1,419	51	128	54
Uprise D3	Vitamin D3	Vitamins / Minerals / Nutrients	Sub Chronic	1,306	51	95	-16
Ondem	Ondansetron	Gastro Intestinal	Acute	1,214	13	111	16
			Overall	57,882	18.6	5,355	21.2


Source: AIOCD

Fig 21 – Performances of its topbrands




Source: AIOCD

Fig 22 – Growth across key therapies



Source: AIOCD

Fig 23 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## AstraZeneca India

Fig 24– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Brilinta	Ticagrelor	Cardio	Chronic	1,574	0.1	150	18.3
Forxiga	Dapagliflozin	Diabetes	Chronic	1,097	-20.6	113	19.3
Crestor	Rosuvastatin	Cardio	Chronic	530	-1.5	43	5.5
Seloken	Dapagliflozin + Metformin	Diabetes	Chronic	492	4.8	41	0.3
Xigduo	Metoprolol	Cardio	Chronic	443	-14.0	32	-15.4
Betaloc	Metoprolol	Cardio	Chronic	358	-10.4	28	-13.1
Tagrisso	Isosorbide	Cardio	Chronic	311	1.2	25	-17.4
Zoladex	Osimertinib	Oncology	Acute	294	43.0	26	109.3
Imdur	Saxagliptin+Metformin	Diabetes	Chronic	272	-8.5	22	-9.8
Kombiglyze	Goserelin	Hormones	Chronic	210	-11.3	17	2.5
		Overall		6,481	-2.8	581	12.1


Source: AIOCD

Fig 25 – Performances of its top brands




Source: AIOCD

Fig 26 – Growth across key therapies



Source: AIOCD

Fig 27 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Biocon

Fig 28– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Insugen	Human Premix Insulin	Anti Diabetic	Chronic	1,193	5	94	-5
Basalog	Glargine	Anti Diabetic	Chronic	886	9	68	-2
BiomabEgfr	Nimotuzumab	Anti-Neoplastics	Acute	363	91	32	114
Canmab	Trastuzumab	Anti-Neoplastics	Acute	288	-6	7	-66
Psorid	Cyclosporin	Anti-Neoplastics	Sub Chronic	264	23	25	43
Insugen R	Regular Human Insulin	Anti Diabetic	Chronic	262	5	21	9
BiopiperTz	Piperacillin + Tazobactam	Anti-Infectives	Acute	217	181	9	-22
Erypro	Epoetin Alfa	Blood Related	Chronic	168	-52	7	-70
Insugen N	Neutral Protaminated Hagedorn	Anti Diabetic	Chronic	117	47	9	14
Alzumab L	Itolizumab	Anti-Infectives	Acute	108	-	8	-
		Overall		5,206	14.7	384	3.8


Source: AIOCD

Fig 29 – Performances of its top brands



Source: AIOCD

Fig 30 – Growth across key therapies



Source: AIOCD

Fig 31 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD

## Cipla

Fig 32– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Cipremi	Remdesivir	Anti-Infectives	Acute	3,655	3,471.8	174	187.8
Foracort	Formoterol + Budesonide	Respiratory	Chronic	3,632	8.2	335	31.7
Duolin	Levosalbutamol + Ipratropium	Respiratory	Chronic	2,734	15.2	245	28.6
Budecort	Budesonide	Respiratory	Chronic	2,659	10.6	217	38.0
Asthalin	Salbutamol	Respiratory	Chronic	2,085	5.5	162	0.9
Seroflo	Salmeterol + Fluticasone	Respiratory	Chronic	2,046	3.2	151	-8.5
MontairLc	Montelukast + Levocetirizine	Respiratory	Acute	2,022	0.2	144	-14.1
Azee	Azithromycin	Anti-Infectives	Acute	1,958	39.8	152	-2.1
Actemra	Tocilizunab	Anti-Neoplastics	Acute	1,671	489.8	60	-58.8
Dytol	Torsemide	Cardiac	Chronic	1,508	6.8	132	4.9
		Overall		81,170	19.8	6,740	12.6


Source: AIOCD

Fig 33 – Performances of its top brands




Source: AIOCD

Fig 34 – Growth across key therapies



Source: AIOCD

Fig 35 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Dr Reddy's Labs

Fig 36– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Omez	Omeprazole	Gastro Intestinal	Sub Chronic	1,993	18.6	177	10.1
Omez D	Domperidone + Omeprazole	Gastro Intestinal	Acute	1,703	25.6	149	14.1
Atarax	Hydroxyzine	Derma	Acute	1,271	1.4	127	13.3
Stamlo	Amlodipine	Cardiac	Chronic	1,263	31.4	113	28.3
Razo D	Domperidone + Rabeprazole	Gastro Intestinal	Acute	1,209	29.6	100	16.3
Econorm	Saccharomyces Boulardii	Gastro Intestinal	Acute	1,178	25.0	110	47.1
DoxSI	Doxycycline + Lactobacillus	Anti-Infectives	Acute	1,136	129.0	88	43.4
Ketorol	Ketorolac	Pain / Analgesics	Acute	1,076	29.7	88	6.5
Bro Zedex	Guaifenesin + Terbutaline + Bromhexine	Respiratory	Acute	1,039	-4.8	100	66.6
Reclimet	Gliclazide + Metformin	Anti Diabetic	Chronic	921	26.6	73	23.8
		Overall		48,159	15.4	4,326	26.4


Source: AIOCD

Fig 37 – Performances of its topbrands




Source: AIOCD

Fig 38 – Growth across key therapies



Source: AIOCD

Fig 39 – Growth break-up for the company and its top 5 brands (%)



Source: AIOCD


## Eris Lifesciences

Fig 40 – Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Glimisave M	Glimepiride + Metformin	Anti Diabetic	Chronic	1,364	14.3	105	-4.7
Renerve Plus	Methylcobalamin Combinations	Vitamins / Minerals / Nutrients	Sub Chronic	1,115	22.6	85	2.1
GlimisaveMv	Voglibose + Metformin + Glimepiride	Anti Diabetic	Chronic	920	10.3	85	20.8
Tendia M	Teneligliptin + Metformin	Anti Diabetic	Chronic	415	-5.1	38	5.0
Remylin D	Vitamin D + Methylcobalamin Combinations	Vitamins / Minerals / Nutrients	Sub Chronic	410	-13.6	32	1.1
EritelCh	Telmisartan + Chlorthalidone	Cardiac	Chronic	379	-8.8	30	-20.6
Tayo 60K	Vitamin D3	Vitamins / Minerals / Nutrients	Sub Chronic	359	64.6	23	-4.3
Zomelis Met	Vildagliptin + Metformin	Anti Diabetic	Chronic	356	156.9	32	34.1
Lnbloc	Cilnidipine	Cardiac	Chronic	323	-2.5	26	-8.4
Rabonik D	Domperidone + Rabeprazole	Gastro Intestinal	Acute	308	22.7	19	-30.2
			Overall	15,729	14.9	1,338	13.6


Source: AIOCD

Fig 41 – Performances of its topbrands




Source: AIOCD

Fig 42 – Growth across key therapies



Source: AIOCD

Fig 43 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## FDC India

Fig 44–Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Electral	Oral Rehydration Salt	Gastro Intestinal	Acute	2,283	28.7	167	17.8
Zifi	Cefixime	Anti-Infective	Acute	2,221	9.7	249	57.4
Enerzal	Oral Rehydration Salt	Gastro Intestinal	Acute	756	48.2	64	30.2
ZifiCv	Cefixime + Clavulanic Acid	Anti-Infective	Acute	543	22.7	68	82.5
Vitcofol	Nicotinamide + Folic Acid + Cyanocobalamin	Vitamins	Chronic	536	24.4	52	33.7
Zocon	Fluconazole	Anti-Infective	Acute	523	3.9	48	18.9
Zathrin	Azithromycin	Anti-Infective	Acute	444	50.5	46	58.8
Zifi O	Cefixime + Ofloxacin	Anti-Infective	Acute	415	45.3	44	62.6
Amodep At	Amlodipine + Atenolol	Cardiac	Chronic	364	8.9	25	-12.7
Favenza	Favipiravir	Anti-Infective	Acute	307	-	16	-
		Overall		13,587	22.0	1,252	33.6

Source: AIOCD


Fig 45 – Performances of its topbrands



Source: AIOCD


Source: AIOCD

Fig 46 – Growth across key therapies



Source: AIOCD

Fig 47 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Glenmark Pharma

Fig 48–Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Fabiflu	Favipiravir	Anti-infective	Acute	8,994	498.2	162	-78.9
Telma	Telmisartan	Cardiac	Chronic	3,359	7.1	212	-22.3
Telma H	Telmisartan + Hydrochlorothiazide	Cardiac	Chronic	2,064	-10.2	119	-35.6
Candid	Clotrimazole	Derma	Sub Chronic	1,406	-2.8	117	-26.5
Telma Am	Telmisartan + Amlodipine	Cardiac	Chronic	1,397	-3.5	96	-15.9
Ascoril Plus	Guaifenesin + Terbutaline + Bromhexine	Respiratory	Acute	1,262	7.0	99	5.5
Candid-B	Beclomethasone + Clotrimazole	Derma	Sub Chronic	1,147	8.3	96	-7.8
Ascoril Ls	Levosalbutamol + Ambroxol + Guaifenesin	Respiratory	Acute	1,111	-6.6	127	92.2
Ascoril D Plus	Phenylephrine + Cpm + Dextromethorphan	Respiratory	Acute	815	-	76	-
Zita-Met Plus	Teneligliptin + Metformin	Anti Diabetic	Chronic	786	-3.2	61	-10.1
		Overall		43,807	28.9	2,882	-17.0


Source: AIOCD

Fig 49 – Performances of its topbrands




Source: AIOCD

Fig 50 – Growth across key therapies



Source: AIOCD

Fig 51 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## GSK Pharma

Fig 52–Performances of its topbrands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Augmentin	Amoxycillin + Clavulanic Acid	Anti-Infectives	Acute	4,955	8.9	607	51.1
Calpol	Paracetamol	Pain / Analgesics	Acute	3,300	37.3	390	88.1
Betnovate N	Betamethasone + Neomycin	Derma	Sub Chronic	2,592	32.7	233	26.4
T Bact	Mupirocin	Derma	Acute	2,481	28.4	259	29.9
Betnovate C	Betamethasone + Clioquinol	Derma	Chronic	2,470	14.9	151	-5.7
Eltroxin	Levo-Thyroxine	Hormones	Chronic	2,304	8.9	189	18.9
Ceftum	Cefuroxime	Anti-Infectives	Acute	2,209	34.4	227	32.8
Synflorix	Pneumonia	Vaccines	Acute	2,124	-22.3	122	-43.7
InfanrixHexa	All Other Vaccines	Vaccines	Acute	1,314	7.5	92	-17.1
Betnesol	Betamethasone	Hormones	Acute	1,251	9.1	121	41.4
		Overall		41,820	8.8	3,852	18.6


Source: AIOCD

Fig 53 – Performances of its top brands




Source: AIOCD

Fig 54 – Growth across key therapies



Source: AIOCD

Fig 55 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD

## Indoco Remedies

Fig 56–Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Cyclopam	Dicyclomine + Paracetamol	Pain	Chronic	1,144	20.3	111	39.1
Atm	Azithromycin	Anti-Infectives	Acute	872	61.7	94	50.8
Febrex Plus	Phenylephrine	Respiratory	Acute	829	-2.1	97	62.8
Karvol Plus	Cefpodoxime	Anti-Infectives	Acute	688	78.3	38	-26.6
Sensodent-K	Potassium Nitrate	Stomatologicals	Chronic	654	18.6	62	7.9
Cital	Disodium Hydrogen Citrate	Urology	Acute	521	14.6	47	12.0
Oxipod	Menthol + Terpinol	Respiratory	Acute	408	-5.9	65	165.0
Sensoform	Strontium Chloride	Stomatologicals	Chronic	349	17.4	32	9.2
Sensodent-Kf	Potassium Nitrate	Stomatologicals	Chronic	317	12.0	31	11.2
Cloben G	Clotrimazole / Beclometasone	Gynaecology	Acute	244	0.3	25	4.6
		Overall		10,474	15.4	1,020	33.0


Source: AIOCD

Fig 57 – Performances of its topbrands




Source: AIOCD

Fig 58 – Growth across key therapies



Source: AIOCD

Fig 59 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## IPCA

Fig 60– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Zerodol Sp	Aceclofenac + Paracetamol + Serratiopeptidase	Pain Management	Chronic	3,069	43.3	313	42.1
Zerodol P	Aceclofenac + Paracetamol	Pain Management	Chronic	1,989	39.0	252	25.1
Hcqs	Hydroxychloroquine	Rheumatology Drugs	Chronic	1,537	-6.7	127	-25.2
Folitrax	Methotrexate	Rheumatology Drugs	Chronic	828	15.1	78	28.5
Zerodol Th	Thiocolchicoside + Aceclofenac	Pain Management	Chronic	791	29.8	75	26.0
Glycinorm M	Gliclazide	Anti-Diabetic	Chronic	604	19.2	49	21.3
Ctd	Chlorthalidone	Cardio	Chronic	596	13.8	57	30.0
Ctd-T	Telmisartan + Chlorthalidone	Cardio	Chronic	595	16.1	60	33.5
Lariago	Chloroquine	Anti-Malarial	Acute	571	10.6	74	69.5
Saaz	Sulfasalazine	Rheumatology Drugs	Chronic	541	9.4	47	12.3
		Overall		26,609	22.6	2,769	38.5


Source: AIOCD

Fig 61 – Performances of its top brands




Source: AIOCD

Fig 62 – Growth across key therapies



Source: AIOCD

Fig 63 – Growth break-up for the company and its top 5 brands (%)



Source: AIOCD


## JB Chemicals

Fig 64– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Cilacar	Cilnidipine	Cardio	Chronic	1,988	6.9	162	-1.2
Rantac	Ranitidine	Gastro Intestinal	Acute	1,907	14.6	170	-3.8
Metrogyl	Metronidazole	Gastro Intestinal	Acute	895	22.7	70	3.6
Nicardia	Nifedipine	Cardio	Chronic	835	-10.8	66	-3.2
Cilacar T	Cilnidipine + Telmisartan	Cardio	Chronic	713	18.7	63	18.7
Rantac Dom	Domperidone + Ranitidine	Gastro Intestinal	Acute	210	8.9	18	4.9
Contrapaque	Iohexol	Others	Acute	171	1.6	14	-9.3
Cilacar M	Cilnidipine + Metoprolol Succinate	Cardio	Chronic	164	9.4	14	0.4
Metrogyl P	Metronidazole	Gastro Intestinal	Acute	156	12.8	13	6.3
Gutpro	Probiotic	Gastro Intestinal	Acute	139	186.0	9	119.9
Overall				8,765	10.1	721	1.0


Source: AIOCD

Fig 65 – Performances of its top brands




Source: AIOCD

Fig 66 – Growth across key therapies



Source: AIOCD

Fig 67 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Lupin

Fig 68– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Gluconorm-G	Glimepiride + Metformin	Anti Diabetic	Chronic	2,825	8.6	223	-1.5
Huminsulin	Human Premix Insulin	Anti Diabetic	Chronic	1,820	0.5	127	-16.5
Budamate	Formoterol + Budesonide	Respiratory	Chronic	1,500	8.4	133	27.7
Cidmus	Sacubitril + Valsartan	Cardiac	Chronic	1,341	25.4	110	21.0
Ondero	Linagliptin	Anti Diabetic	Chronic	1,275	12.9	86	-5.3
Gibtulio	Empagliflozin	Anti Diabetic	Chronic	1,231	-3.9	88	-18.8
Ivabrad	Ivabradine	Cardiac	Chronic	1,098	14.4	91	19.4
Tonact	Atorvastatin	Cardiac	Chronic	1,008	3.5	80	4.2
Ondero Met	Linagliptin + Metformin	Anti Diabetic	Chronic	966	3.8	71	-6.7
Ajuduo	Empagliflozin + Linagliptin	Anti Diabetic	Chronic	914	15.3	77	12.4
		Overall		61,925	13.4	5,155	14.6


Source: AIOCD

Fig 69 – Performances of its top brands




Source: AIOCD

Fig 70 – Growth across key therapies



Source: AIOCD

Fig 71 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Natco Pharma

Fig 72– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Velpanat	Sofosbuvir + Velpatasvir	Anti-Infectives	Acute	1,648	-4.5	128	-0.6
Geftinat	Gefitinib	Anti-Neoplastics	Acute	1,359	10.9	66	-28.1
Lenalid	Lenalidomide	Anti-Neoplastics	Sub Chronic	742	7.0	47	-9.1
Veenat	Imatinib Mesylate	Anti-Neoplastics	Acute	623	-25.9	45	15.3
Sorafenat	Sorafenib	Anti-Neoplastics	Acute	503	3.7	26	-27.6
Erlonat	Erlotinib	Anti-Neoplastics	Acute	420	-59.6	1	-98.8
Zoldonat	Zoledronate	Pain / Analgesics	Sub Chronic	293	5.1	15	-30.1
Apigat	Apixaban	Blood Related	Acute	173	-	13	-
Hepcinat Plus	Sofosbuvir + Daclatasvir	Anti-Infectives	Acute	172	1.6	5	-57.8
Fulvenat	Fulvestrant	Anti-Neoplastics	Acute	156	6.6	8	-24.4
Overall				7,742	-25.9	511	-31


Source: AIOCD

Fig 73 – Performances of its top brands




Source: AIOCD

Fig 74 – Growth across key therapies



Source: AIOCD

Fig 75 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Pfizer

Fig 76– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Becosules	Vitamin B Complex With Vitamin C	Vitamins / Minerals / Nutrients	Sub Chronic	4,152	14.7	325	-14.1
Mucaine	Oxetocaine + Aluminium + Magnesium	Gastro Intestinal	Acute	2,170	24.0	206	17.0
GelusilMps	Aluminium + Dimethicone + Magnesium	Gastro Intestinal	Acute	2,045	4.6	165	-7.3
Magnex	Cefoperazone + Sulbactum	Anti-Infectives	Acute	1,954	1.7	144	-0.4
Minipress XI	Prazosin	Cardiac	Chronic	1,763	12.0	163	27.8
Wysolone	Prednisolone	Hormones	Acute	1,712	24.8	149	18.5
Dolonex	Piroxicam	Pain / Analgesics	Acute	1,670	-2.2	152	7.8
Eliquis	Apixaban	Blood Related	Acute	1,658	105.6	101	-5.4
CorexDx	Chlorpheniramine + Dextromethorphan	Respiratory	Acute	1,585	14.5	170	89.5
Dalacin C	Clindamycin	Anti-Infectives	Acute	1,191	13.1	108	23.5
		Overall		38,548	12.3	3,218	8.2


Source: AIOCD

Fig 77 – Performances of its topbrands




Source: AIOCD

Fig 78 – Growth across key therapies



Source: AIOCD

Fig 79 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Sanofi

Fig 80– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Lantus	Glargine	Anti Diabetic	Chronic	5,675	8.1	475	6.4
Combiflam	Ibuprofen + Paracetamol	Pain / Analgesics	Acute	2,186	12.1	196	7.0
Clexane	Enoxaparin	Cardiac	Chronic	2,055	50.4	131	-46.2
Allegra	Fexofenadine	Respiratory	Acute	1,726	-6.1	168	21.8
Amaryl M	Glimepiride + Metformin	Anti Diabetic	Chronic	1,534	-0.2	134	14.8
Avil	Pheniramine	Respiratory	Acute	1,306	20.3	106	0.3
Hexaxim	Combinations With Tetanus Component	Vaccines	Acute	1,275	-12.6	94	-9.6
Fluquadri	Influenza	Vaccines	Acute	1,219	9.3	100	-26.1
Enterogermina	Bacillus Clausii	Gastro Intestinal	Acute	1,165	37.3	110	74.2
Dulcoflex	Bisacodyl	Gastro Intestinal	Acute	1,092	112.7	108	94.1
		Overall		35,858	12.0	3,096	9.2


Source: AIOCD

Fig 81 – Performances of its topbrands




Source: AIOCD

Fig 82 – Growth across key therapies



Source: AIOCD

Fig 83 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Sun Pharma

Fig 84 – Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Volini	Diclofenac	Pain / Analgesics	Acute	3,517	26.8	336	19.3
Rosuvas	Rosuvastatin	Cardiac	Chronic	3,394	12.9	302	17.4
Levipil	Levetiracetam	Neuro / Cns	Chronic	3,027	1.7	241	-0.4
Gemer	Glimepiride + Metformin	Anti Diabetic	Chronic	2,444	7.7	201	8.2
Istamet	Sitagliptin + Metformin	Anti Diabetic	Chronic	2,396	-6.0	196	1.9
Susten	Natural Micronised Progesterone	Gynaecological	Sub Chronic	2,104	9.2	179	30.1
Pantocid	Pantoprazole	Gastro Intestinal	Sub Chronic	2,015	11.8	176	17.9
Revital H	Ginseng Products	Vitamins / Minerals / Nutrients	Acute	1,957	31.5	144	-20.8
Montek-Lc	Montelukast + Levocetirizine	Respiratory	Acute	1,919	31.2	146	10.3
PantocidDsr	Domperidone + Pantoprazole	Gastro Intestinal	Acute	1,914	16.8	162	9.6
		Overall		131,569	12.7	11,527	20.9


Source: AIOCD

Fig 85 – Performances of its top brands




Source: AIOCD

Fig 86 – Growth across key therapies



Source: AIOCD

Fig 87 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Torrent Pharma

Fig 88 – Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Shelcal	Calcium Carbonate + Vit D3	Vitamins / Minerals / Nutrients	Sub Chronic	2,821	19.6	236	4.3
Chymoral Forte	Chymotrypsin + Trypsin	Pain / Analgesics	Acute	1,726	14.3	163	28.7
Nexpro Rd	Domperidone + Esomeprazole	Gastro Intestinal	Acute	1,419	30.4	131	29.2
Nikoran	Nicorandil	Cardiac	Chronic	1,356	8.3	116	16.9
Azulix-Mf	Glimepiride + Metformin	Anti Diabetic	Chronic	1,114	3.8	94	15.6
Nebicard	Nebivolol	Cardiac	Chronic	1,080	6.6	91	18.0
ShelcalXt	Other Calcium Combinations	Vitamins / Minerals / Nutrients	Sub Chronic	1,031	23.6	104	50.1
Unienzyme	Digestive Enzymes	Gastro Intestinal	Acute	1,019	12.1	86	2.7
Losar H	Losartan + Hydrochlorothiazide	Cardiac	Chronic	999	5.0	80	1.4
Losar	Losartan	Cardiac	Chronic	959	3.8	85	8.5
		Overall		50,151	13.2	4,497	22.5



Source: AIOCD

Fig 89 – Performances of its top brands




Source: AIOCD

Fig 90 – Growth across key therapies



Source: AIOCD

Fig 91 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD


## Zydus Cadila

Fig 92– Performances of its top-10 brands

Brands	Molecule	Therapy	Chronic/Acute	MAT Aug sales (Rsm)	Growth (%)	Aug sales (Rsm)	Growth (%)
Remdac	Remdesivir	Anti-Infectives	Acute	2,272	2,951.3	46	-38.5
Deriphyllin	Theophylline + Etophylline	Respiratory	Acute	1,814	9.8	137	15.1
Atorva	Atorvastatin	Cardiac	Chronic	1,787	5.2	152	5.7
Mifegest Kit	Mifepristone + Misoprostol	Gynaecological	Acute	1,673	3.4	141	-2.0
Skinlite	Hydroquinone + Mometasone + Tretinoin	Derma	Chronic	1,351	-4.4	94	-16.1
Vorier	Voriconazole	Anti-Infectives	Acute	1,312	151.3	87	91.5
Thrombophob	Unfractionated Heparins	Pain / Analgesics	Chronic	1,301	21.3	106	23.7
Pantodac	Pantoprazole	Gastro Intestinal	Sub Chronic	1,236	-3.1	86	-15.3
Dexona	Dexamethasone	Hormones	Acute	1,215	3.6	90	-8.3
DecaDurabolin	Nandrolone	Hormones	Acute	1,211	4.2	102	-2.5
		Overall		67,935	14.4	5,607	11.9


Source: AIOCD

Fig 93 – Performances of its topbrands




Source: AIOCD

Fig 94 – Growth across key therapies



Source: AIOCD

Fig 95 – Growth break-up for the company and its top-5 brands (%)



Source: AIOCD

## Appendix

### Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

### Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)	Buy	Hold	Sell
Large Caps (>US\$1bn)	>15%	5-15%	<5%
Mid/Small Caps (<US\$1bn)	>25%	5-25%	<5%

### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity) is a subsidiary of Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX) and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged in the business of Stock Broking, Depository Participant and Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

**General Disclaimer:** This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. ARSSBL does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding taxation aspects of any potential investment.

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. [www.rathionline.com](http://www.rathionline.com)

**Disclaimers in respect of jurisdiction:** This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

#### **Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates**

#### **Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report**

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No

#### **Other Disclosures pertaining to distribution of research in the United States of America**

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2021. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.  
Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.